Bruker (BRKR) AI Stock Analysis

• Market Cap: $5.87B
• Dividend Yield: 0.52%
• Average Volume (3M): 3.81M
• Price to Earnings (P/E): 73.9
• Beta (1Y): 1.17
• Revenue Growth: 10.36%
• EPS Growth: -78.26%
• Country: US
• Employees: 11,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.32
• Shares Outstanding: 151,719,360
• 10 Day Avg. Volume: 3,432,242
• 30 Day Avg. Volume: 3,810,824
• PEG Ratio: -1.04
• Price to Book (P/B): 4.90
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 64.22
• Enterprise Value/Market Cap: 1.47
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 5.24
• Enterprise Value/Ebitda: 21.62
• 1Y Price Target: $44.56
• Price Target Upside: 15.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 64 Neutral
• Price Target: $41.00 ▲(5.89% Upside)

Bruker's overall stock score reflects a challenging financial environment with declining revenue and profitability, compounded by cash flow issues. Technical analysis shows short-term bullish momentum, but valuation concerns arise from a high P/E ratio. The earnings call highlighted both strategic initiatives and significant market challenges, contributing to a cautious outlook.

Positive Factors

Product Innovation

Bruker's focus on product innovation strengthens its competitive edge in key markets, supporting long-term growth and market leadership.

Strategic Partnerships

Partnerships with leading research institutions enhance Bruker's market position, driving demand for its advanced scientific instruments.

Cost Savings Initiative

The cost savings initiative will improve margins and financial health, providing a buffer against market volatility and enhancing profitability.

Negative Factors

Revenue Decline

Declining revenue signals challenges in market demand and operational execution, potentially impacting long-term growth prospects.

Rising Leverage

Increased leverage can strain financial flexibility and elevate risk, necessitating careful debt management to maintain stability.

Cash Flow Pressures

Declining cash flow limits Bruker's ability to invest in growth and innovation, potentially hindering long-term strategic initiatives.

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

How the Company Makes Money

Bruker generates revenue through multiple streams, primarily from the sale of its scientific instruments and related services. The company markets its products to a diverse range of sectors, including academic research, pharmaceuticals, biotechnology, and environmental testing. Key revenue streams include instrument sales, service contracts, and consumables that support ongoing operations of the instruments. Additionally, Bruker benefits from partnerships and collaborations with research institutions and pharmaceutical companies, which can lead to increased sales and joint development opportunities. The company's focus on innovation and expanding its product portfolio, along with a strong customer base, contributes significantly to its earnings.

Bruker Financial Statement Overview

Summary

Bruker faces a challenging financial landscape with declining revenue growth and profitability. The balance sheet shows increased leverage, and cash flow issues are evident with significant declines in free cash flow growth. To improve financial health, Bruker must enhance revenue growth, manage debt levels, and improve cash flow generation.

Income Statement

Bruker's income statement shows a mixed performance. The TTM data reveals a decline in revenue growth rate by 9.6%, indicating a slowdown compared to previous periods. Gross profit margin remains stable at around 48%, but net profit margin has decreased to 2.31%, reflecting reduced profitability. EBIT and EBITDA margins have also contracted, suggesting operational challenges. Despite these issues, the company has shown resilience in maintaining a positive gross profit margin.

Balance Sheet

The balance sheet indicates a moderate financial position. The debt-to-equity ratio has increased to 1.34 in the TTM, highlighting rising leverage, which could pose a risk if not managed. Return on equity has decreased to 4.40%, reflecting lower profitability for shareholders. However, the equity ratio remains healthy, indicating a stable asset base. The company needs to manage its debt levels to maintain financial stability.

Cash Flow

Bruker's cash flow statement shows significant challenges. The TTM free cash flow growth rate has sharply declined by 71.76%, indicating cash flow pressures. The operating cash flow to net income ratio is low at 0.12, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is also low at 0.30, indicating potential liquidity constraints. The company needs to improve its cash flow management to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.44B	3.37B	2.96B	2.53B	2.42B	1.99B
Gross Profit	1.65B	1.65B	1.51B	1.31B	1.21B	939.80M
EBITDA	400.30M	438.60M	599.00M	545.30M	497.10M	320.70M
Net Income	79.60M	113.10M	427.20M	296.60M	277.10M	157.80M
Balance Sheet
Total Assets	6.34B	5.81B	4.25B	3.62B	3.65B	3.05B
Cash, Cash Equivalents and Short-Term Investments	92.00M	183.40M	488.30M	645.50M	1.17B	731.80M
Total Debt	2.44B	2.25B	1.38B	1.22B	1.33B	891.50M
Total Liabilities	4.47B	3.99B	2.84B	2.49B	2.57B	2.07B
Stockholders Equity	1.82B	1.78B	1.38B	1.13B	1.08B	975.60M
Cash Flow
Free Cash Flow	49.30M	136.00M	243.20M	143.00M	190.40M	235.00M
Operating Cash Flow	165.90M	251.30M	350.10M	262.00M	282.40M	333.20M
Investing Cash Flow	-245.40M	-1.76B	-326.00M	-239.30M	-192.40M	-193.70M
Financing Cash Flow	-33.30M	1.23B	-193.40M	-415.20M	318.70M	-161.60M

Bruker Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 38.72 is above the 20-day moving average (MA) of 36.97, above the 50-day MA of 34.23, and below the 200-day MA of 40.77, indicating a neutral trend. The MACD of 1.45 indicates Negative momentum. The RSI at 61.10 is Neutral, neither overbought nor oversold. The STOCH value of 53.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.

Bruker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	―	$8.47B	24.22	8.62%	―	17.43%	775.48%
BIO	―	$8.94B	28.16	4.59%	―	-0.33%	―
BRKR	―	$5.87B	73.91	4.43%	0.52%	10.36%	-78.26%
ITGR	―	$2.55B	29.39	5.18%	―	7.81%	-26.32%
LIVN	―	$2.94B	―	-17.87%	―	8.57%	-1154.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GKOS	―	$4.28B	―	-12.98%	―	26.70%	48.19%

Bruker Corporate Events

Bruker Raises $669.5 Million Through Underwriting Agreement

On September 3, 2025, Bruker entered into an underwriting agreement with J.P. Morgan Securities LLC and BofA Securities, Inc. for an offering. The company raised approximately $669.5 million in net proceeds after deducting underwriting discounts and estimated offering expenses.

The most recent analyst rating on (BRKR) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.

Bruker Corporation Faces Challenges Amid Revenue Decline

Bruker Corporation’s recent earnings call highlighted a challenging quarter marked by significant revenue declines and reduced guidance. The company faced headwinds from market conditions, tariffs, and foreign exchange fluctuations. Despite these hurdles, Bruker is taking proactive steps with cost-saving measures and continues to innovate, particularly in diagnostics and new product launches. However, the negative aspects, such as revenue and EPS declines, along with challenges in U.S. academic funding, overshadow the positives.

Bruker Corporation Reports Q2 2025 Financial Results

Bruker Corporation is a leading company in the life sciences sector, specializing in high-performance scientific instruments and analytical solutions that enable breakthroughs in post-genomic discoveries and applications. The company operates across various segments, including life science research, applied and biopharma applications, and industrial research.